Index

A

Academic freedom, fair criticism versus politicization of neuroscience of sex differences, 2–5

ACTH. See Adrenocorticotropic hormone

AD. See Alzheimer’s disease

Adalimumab, adverse drug reactions, 26

Adrenocorticotropic hormone (ACTH)
circadian rhythm, 63
sex differences, 73–75, 88

ADRs. See Adverse drug reactions

Adverse drug reactions (ADRs), sex differences, 22–29

AIS. See Androgen insensitivity syndrome

Aliskiren, adverse drug reactions, 25

Alzheimer’s disease (AD), 149–150

AMH. See Anti-Müllerian hormone

Amlodipine, adverse drug reactions, 25

Amygdala, social behavior network, 48

Androgen insensitivity syndrome (AIS), 134–135

Androgens
depression and stress regulation, 95–96
hypothalamic-pituitary-adrenal axis regulation, 75, 80
perinatal androgens and sex bias of mast cell diseases
brain development and mast cell activity, 108–109
immunoglobulin E-mediated anaphylaxis, 107–108
mast cell granule mediator storage, 108
prenatal exposure. See Digit ratio

Anteroventral periventricular nucleus (AVPV), sex differences, 50, 63

Anti-Müllerian hormone (AMH), 134–135

Arginine vasopressin (AVP)
hypothalamic-pituitary-adrenal axis regulation, 73–74
spotted hyena sex differences, 127

Aripiprazole, adverse drug reactions, 27

Aspirin, adverse drug reactions, 25

AVP. See Arginine vasopressin

AVPV. See Anteroventral periventricular nucleus

B

Basolateral amygdala (BLA), 90, 92

Bed nucleus of the stria terminalis (BNST)
sex differences, 42, 50–51, 53, 55
social behavior network, 48–49
stress response, 88, 94

Behavior, sex differences
automated phenotyping to assess internal and affective states, 40–41
multimodal data stream incorporation, 39
overview, 33–34, 36
quantification without bias
automation, 37–39
historical perspective, 36–37
machine learning, 37–38
tools for discovery, 35

BICCN. See BRAIN Initiative Cell Census Network

BLA. See Basolateral amygdala

Blood pressure, circadian rhythm, 64

BNST. See Bed nucleus of the stria terminalis

Body temperature, circadian rhythm, 64–65

BRAIN Initiative Cell Census Network (BICCN), 51

Brain organization theory, 6

Buprenorphine, adverse drug reactions, 26

Bupropion, adverse drug reactions, 27

C

CAH. See Congenital adrenal hyperplasia

Cannabis, adverse drug reactions, 28

Captopril, adverse drug reactions, 26

Carbamazepine, adverse drug reactions, 26

Chronic social defeat stress (CSDS), 86–88

Circadian rhythm, sex differences
blood pressure, 64
body temperature, 64–65
disruption effects, 66–67
heart rate variability, 63–64
hypothalamic pituitary adrenal axis, 62
hypothalamic pituitary gonadal axis, 62–63
immune response, 65
neuroanatomy, 62
overview, 61–62
prospects for study, 67
sleep–wake rhythms, 65–66
Index

Citalopram, adverse drug reactions, 27
Clopidogrel, adverse drug reactions, 25
Clozapine, adverse drug reactions, 27
Congenital adrenal hyperplasia (CAH), 6–8, 132, 134–135
COVID-19
  cell lines for study, 23
  sex differences, 111
CRISPR, 54
CSDS. See Chronic social defeat stress
CUT&RUN, 54
Cyclosporin, adverse drug reactions, 26
Dabigatran, adverse drug reactions, 25
Dafefenacin, adverse drug reactions, 25
Darting behavior, sex differences, 35, 40
  mapping to sex differences in nervous system, 41–42
  sex differences as individual differences, 42
DeepLabCut, 35, 37
DeepPoseKit, 37
DeepSqueak, 39
Dentate gyrus (DG), 89, 91
Depression. See Major depressive disorder
Developmental systems theory, 6–7
DG. See Dentate gyrus
Diazepam, adverse drug reactions, 27
Digit ratio
  androgen insensitivity syndrome, 134–135
  gay men, 136–139
  lesbians, 135
  sensitivity as individual difference measure, 9
Digoxin, adverse drug reactions, 25
Dihydrotestosterone. See Androgens
Dofetilide, adverse drug reactions, 25

E
EAE. See Experimental autoimmune encephalomyelitis
Elevated plus maze (EPM), 87
Epigenetics, brain sexual differentiation
  ERα neural targets, 53–54
  gene expression, sex differences, 53
  neural circuit organization, 48–51
  neuron dimorphism and cell identity, 51
  overview, 48, 51–53
  prospects for study, 55–56
EPM. See Elevated plus maze
ERP. See Event-related potential
Erythromycin, adverse drug reactions, 26
ERα. See Estrogen receptor α
Estradiol
  hypothalamic-pituitary-adrenal axis modulation, 74–75, 79–80
  mast cell response, 109
Estrogen receptor α (ERα)
  gene regulatory signature in perinatal period, 54–55
  hypothalamic-pituitary-adrenal axis sex differences, 75, 80
  neural targets, 53–54
Eszopiclone, adverse drug reactions, 27
Event-related potential (ERP), sex differences in stress response, 79
Experimental autoimmune encephalomyelitis (EAE), sex differences, 106–107

F
FCG model. See Four core genotypes model
Female rodents
  exclusion from preclinical studies, 16, 19–22
HPA axis. See Hypothalamic-pituitary-adrenal axis
  trait variability, 19–20
Finasteride, spotted hyena development studies, 122, 126–127
Fluorouracil, adverse drug reactions, 26
Fluoxetine, adverse drug reactions, 27
Flutamide, spotted hyena development studies, 122, 126
fMRI. See Functional magnetic resonance imaging
Forced swim test (FST), 87, 95–96
Four core genotypes (FCG) model, 149–150
FST. See Forced swim test
Functional magnetic resonance imaging (fMRI)
  hippocampus–nucleus accumbens connectivity, 92
  Trier Social Stress Test studies, 78

G
Gabapentin, adverse drug reactions, 26
Gonadotropin-releasing hormone. See Isolated gonadotropin-releasing hormone deficiency

H
hCG. See Human chorionic gonadotropin
Heart rate variability, circadian rhythm, 63–64
Heparin, adverse drug reactions, 25
Hippocampus, stress, depression, and sex differences, 91–94
HPA axis. See Hypothalamic-pituitary-adrenal axis
Human chorionic gonadotropin (hCG), 139–140
Hypothalamic-pituitary-adrenal (HPA) axis. See also Stress response
circadian rhythm, 62
human studies of sex differences, 76–79
prospects for study, 79–80
rodent studies
regulation, 72–73
sex differences
androgen regulation, 75, 80
estradiol modulation, 74–75
functional differences, 73–74, 88–91
negative feedback regulation, 74
organized actions of gonadal steroids, 75–76

I
IGD. See Isolated gonadotropin-releasing hormone deficiency
Imipramine, adverse drug reactions, 27
Immune response, circadian rhythm, 65
Immunoglobulin E-mediated anaphylaxis, sex differences, 105–106
Inductive risk, fair criticism versus politicization of neuroscience of sex differences, 8–11
Infliximab, adverse drug reactions, 26
Interactive objectivity, 7–8
Isolated gonadotropin-releasing hormone deficiency (IGD)
androgen exposure in development, 139–140
sexual orientation, 140–142

K
Kdm5c, 154
Kdm6a, 150
Ketamine, adverse drug reactions, 26

L
LEAP, 37
Levofoxacin, adverse drug reactions, 26
LH. See Luteinizing hormone
Liraglutide, adverse drug reactions, 25
Long-term depression (LTD), 92
Long-term potentiation (LTP), 93–94
Losartan, adverse drug reactions, 25
LTD. See Long-term depression
LTP. See Long-term potentiation
Luteinizing hormone (LH), circadian rhythm, 63

M
Major depressive disorder (MDD)
animal models, 86–88
sex differences in rates, 86
stress response
depression, and sex differences
hippocampus, 91–94
hormone signaling in brain, 94–96
nucleus accumbens, 91–94
prospects for study, 96–97
sex differences, 88–91
MAP-2, 96
MARS, 37
Mast cell
estrous cycle and estrogen effects on mast cell numbers, 109
evolutionary perspective of sex differences, 111
functional overview, 103–104
prospects for study, 111–113
sex chromosome complement influences, 110–111
sex differences in diseases
experimental autoimmune encephalomyelitis, 106–107
immunoglobulin E-mediated anaphylaxis, 105–106
multiple sclerosis, 106–107
perinatal androgens and sex bias of diseases
brain development and mast cell activity, 108–109
immunoglobulin E-mediated anaphylaxis, 107–108
mast cell granule mediator storage, 108
sex hormone interactions, 109–110
MDD. See Major depressive disorder
MDMA, adverse drug reactions, 28
Medial prefrontal cortex (mPFC), 90, 95
Medial preoptic area (MPOA)
sex differences, 108–109
social behavior network, 49–50
Methylphenidate, adverse drug reactions, 27
Mirabegron, adverse drug reactions, 25
Morphine, adverse drug reactions, 26
mPFC. See Medial prefrontal cortex
MPOA. See Medial preoptic area
MS. See Multiple sclerosis
Multiple sclerosis (MS), sex differences, 106–107
MUPET, 39

N
NAc. See Nucleus accumbens
Nortriptyline, adverse drug reactions, 27
Index

NPX, 155
Nucleus accumbens (NAc)
  sex differences, 42
  stress, depression, and sex differences, 91–94

O
Olanzapine, adverse drug reactions, 27
Onuf’s nucleus, spotted hyena, 126–127
Oxycodone, adverse drug reactions, 26

P
Paclitaxel, adverse drug reactions, 26
PAG. See Periaqueductal gray
PAR. See Pseudoautosomal region
Paraventricular nucleus (PVN), hypothalamic-pituitary-adrenal axis sex differences, 73–76, 88
Perampanel, adverse drug reactions, 26
Periaqueductal gray (PAG), sex differences, 41
Pharmacokinetics, sex differences, 22–29
Politization, neurosciencne of sex differences
  academic freedom versus equality, 2–5
  fair criticism distinguishing, 4–5, 7–11
  frameworks, background assumptions and dominant methodologies, 5–8
  inductive risks and social values, 8–10
  overview, 1–2
Posttraumatic stress disorder (PTSD), 91
Pramipexole, adverse drug reactions, 26
Pravastatin, adverse drug reactions, 25
Prednisone, adverse drug reactions, 26
Primaquine, adverse drug reactions, 28
Propranolol, adverse drug reactions, 25
Pseudoautosomal region (PAR), X chromosome, 155
PTSD. See Posttraumatic stress disorder
PVN. See Paraventricular nucleus

R
Ranitidine, adverse drug reactions, 25
Risperidone, adverse drug reactions, 27
Rosiglitazone, adverse drug reactions, 25

S
SABV. See Sex as a biological variable
SCN. See Suprachiasmatic nucleus of the hypothalamus
SCVS. See Subchronic variable stress
SDN-POA. See Sexually dimorphic nucleus
Sertraline, adverse drug reactions, 27
Sex as a biological variable (SABV), 16, 34
Sex-based analysis, historical perspective, 17–19
Sex bias, historical perspective, 16–17
Sexual differentiation
  cell-autonomous sex chromosome effects, 148–151
  divergence of genetic and hormonal conceptual frameworks, 151–152
  education, 155, 157
  evolution
    compensation for other sex differences, 153–155
    sex differences in genome, 152
    four core genotypes model, 149–150
    nongonadal sexual dimorphism on X chromosome, 155–156
    two-step hormonal theory, 147–148, 151
Sexual orientation. See Digit ratio; Isolated gonadotropin-releasing hormone deficiency
Sexually dimorphic nucleus (SDN-POA), 48–51, 55–56
Sleep–wake rhythm, sex differences, 65–66
Spotted hyena, sex differences
  behavior
    aggression and dominance, 119–121
    development of aggression behavior differences, 121–123
    reproduction, 118–119
    space use, 118
  morphology
    body size and shape, 123
    genitalia, 123–126
    nervous system, 126–128
    overview, 117–118, 128–129
Sry, 147–149, 152–154
Stress response. See also Hypothalamic-pituitary-adrenal axis
  depression, stress, and sex differences
    hippocampus, 91–94
    hormone signaling in brain, 94–96
    nucleus accumbens, 91–94
    prospects for study, 96–97
  human studies of sex differences, 76–79
  overview, 71–72
  rodent studies of hypothalamic-pituitary-adrenal axis
    regulation, 72–73
    sex differences
      androgen regulation, 75
      estradiol modulation, 74–75
      functional differences, 73–74, 88–91
      negative feedback regulation, 74
      organized actions of gonadal steroids, 75–76

© 2023 by Cold Spring Harbor Laboratory Press. All rights reserved.
Subchronic variable stress (SCVS), 86, 88, 94
Suprachiasmatic nucleus of the hypothalamus (SCN) circadian rhythm control, 61–62
sex differences, 62–63, 66

T
Terfenadine, adverse drug reactions, 28
Testosterone. See also Androgens fetal metabolism, 48
hypothalamic-pituitary-adrenal axis modulation, 75–76
mast cell interactions, 110
Torasemide, adverse drug reactions, 25
Tramadol, adverse drug reactions, 26
Trier Social Stress Test (TSST), sex differences, 77–78
Trospium, adverse drug reactions, 25
TSST. See Trier Social Stress Test

V
Ventromedial hypothalamus sex differences, 41–42, 49–50
social behavior network, 49
Verapamil, adverse drug reactions, 25
Vigilance behavior, sex differences, 35, 40–41
Voriconazole, adverse drug reactions, 26

W
Warfarin, adverse drug reactions, 25

X
X chromosome, nongonadal sexual dimorphism, 155–156
Xist, 151

Z
Zolmitriptan, adverse drug reactions, 26
Zolpidem, adverse drug reactions, 27